Skip to main content

Chronic Pseudomonas Aeruginosa Infection

2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BiomX
BiomXIsrael - Ness Ziona
2 programs
1
1
BX004Phase 21 trial
BX004-APhase 1/21 trial
Active Trials
NCT05010577Completed43Est. Mar 2024
NCT06998043Recruiting63Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
BiomXBX004
BiomXBX004-A

Clinical Trials (2)

Total enrollment: 106 patients across 2 trials

Study With Phage for CF Subjects With Pseudomonas Lung Infection

Start: Jul 2025Est. completion: Sep 202663 patients
Phase 2Recruiting

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

Start: Jun 2022Est. completion: Mar 202443 patients
Phase 1/2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 106 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.